Frances and Augustus Newman Foundation

The Frances and Augustus Newman Foundation advances medical science through rigorous funding of peer-reviewed research projects addressing major health challenges, emphasizing scientific merit, innovation, and potential for transformative patient outcomes. Core values include evidence-based assessment, strategic resource allocation, and commitment to generating new knowledge and practical medical advances via sustained, multi-year investigations at leading academic institutions. Their impact philosophy prioritizes projects with clear pathways to tangible benefits for patients, favoring expert-reviewed initiatives that propel breakthroughs in diagnosis, treatment, and care over routine services.

They support medical research into cancer including blood cancer research at specialized institutes, brain tumour research targeting aggressive neurological malignancies, muscular dystrophy studies exploring neuromuscular disorders and genetic therapies, neurological disorders encompassing neuro-disability and brain function impairments, and surgical advancements through royal college-led projects. Funding covers defined research posts and direct project costs for investigations yielding clinical insights, therapeutic innovations, and preventive strategies for patients with complex cancers, progressive neuromuscular conditions, debilitating brain tumours, and severe neurological disabilities. They back academic and research centre endeavours generating evidence for improved treatments, patient survival rates, and quality of life enhancements, focusing on high-impact science addressing unmet needs in oncology, neurology, and neuro-rehabilitation.

Exclusions encompass general core funding, capital infrastructure, non-research medical services, social care initiatives, and projects lacking peer-reviewed rigor or scientific potential. Distinctive for its unwavering medical research exclusivity, preference for established UK research institutions over grassroots or service-delivery organizations, and emphasis on multi-year, reviewable grants ensuring accountability and scalability. They prioritize beneficiaries including cancer patients, individuals with muscular dystrophy, those facing brain tumours, people with neurological disorders, and neuro-disabled populations, seeking evidence-based advancements that deliver public health gains through pioneering medical discovery.